A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)
Status:
Completed
Trial end date:
2019-07-22
Target enrollment:
Participant gender:
Summary
This study will assess the safety and efficacy of ixekizumab (LY2439821), compared to
etanercept and placebo in participants with moderate to severe chronic plaque psoriasis.